Negative Conversion of Progesterone Receptor Status after Primary Systemic Therapy Is Associated with Poor Clinical Outcome in Patients with Breast Cancer
Cancer Research and Treatment. 2018;50(4):1418-1432 
Estrogen receptor-β status influences clinical outcome of triple-negative breast cancer
Breast Cancer. 2009;16(4):281-282
Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone
Breast Cancer. 2012;21(2):214-222
Triple Negative Receptor Status is Associated with Poor Outcomes for Lymph Node Positive Breast Cancer Treated with Mastectomy and Modern Systemic Therapy
International Journal of Radiation Oncology*Biology*Physics. 2011;81(2):S218
Clinical pattern of primary systemic therapy and outcomes of estrogen receptor-positive, HER2-negative metastatic breast cancer: a review of a single institution
Breast Cancer Research and Treatment. 2017;166(3):911-917
Analysis of the Pathologic Response to Primary Chemotherapy in Patients with Locally Advanced Breast Cancer Grouped According to Estrogen Receptor, Progesterone Receptor, and HER2 Status
Clinical Breast Cancer. 2007;7(7):559-564
An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer
Breast Diseases: A Year Book Quarterly. 2012;23(3):246-248
Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status
Annals of Oncology. 2006;17(5):818-826
Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index
Clinical Breast Cancer. 2017;17(1):41-47
Influence of younger age to disease outcome in patients with breast cancer after adjuvant systemic chemotherapy and adjuvant hormone therapy
The Breast. 2017;32:S100